checkAd

    DGAP-News  723  0 Kommentare CEVEC introduces CAP(R)Go expression system for scalable production of tailor-made glycoproteins


    DGAP-News: CEVEC Pharmaceuticals GmbH / Key word(s): Product
    Launch/Miscellaneous
    CEVEC introduces CAP(R)Go expression system for scalable production of
    tailor-made glycoproteins

    01.06.2015 / 09:00

    ---------------------------------------------------------------------

    CEVEC introduces CAP(R)Go expression system for scalable production of
    tailor-made glycoproteins

    Cologne, Germany, June 1, 2015 - CEVEC Pharmaceuticals GmbH (CEVEC), a
    global solution and service provider for the production of
    biopharmaceuticals based on a unique human cellular expression system,
    today announced the introduction of the technology platform CAP(R)Go for
    the fully scalable production of tailor-made glycosylated recombinant
    proteins, based on the Company's proprietary CAP(R) technology.

    CAP(R)Go technology - tailor-made glycosylation of recombinant proteins

    With the CAP(R)Go technology, CEVEC addresses an increasing need in the
    pharmaceutical and biotechnology industries for the manufacturing of
    difficult to express therapeutic glycoproteins with tailor-made or fully
    human glycosylation patterns for significantly improved physicochemical and
    pharmacological properties.

    CEVEC's CAP(R)Go expression platform comprises a comprehensive portfolio of
    glyco-optimized human suspension cell lines that differ in their
    glycosylation capabilities and allows for the recombinant production of a
    variety of complexly glycosylated proteins such as high molecular mass
    multimeric proteins including plasma proteins, coagulation factors,
    cytokines and antibodies.

    In previous studies, CAP(R)Go has proven to enhance the activity, stability
    and serum half-life of several candidate proteins. Depending on the
    selected CAP(R)Go cell line, the expressed protein showed: increased
    sialylation for improved half-life; homogenous, serum-like O-glycan
    structures and/or defined N-glycan antennarity, just to name a few.
    Therapeutic proteins expressed on conventional mammalian expression
    platforms like CHO (Chinese hamster ovary) or HEK293 cells (human embryonic
    kidney cells), by contrast, often do not match the glycosylation and
    pharmacokinetic profiles of their plasma-purified counterparts. The
    CAP(R)Go technology provides a highly economic way to manufacture
    glyco-optimized proteins with up to 10 fold higher yields than conventional
    cell lines and offers cost efficient large scale production.
    Seite 1 von 2


    EQS Group AG
    0 Follower
    Autor folgen
    Verfasst von EQS Group AG
    DGAP-News CEVEC introduces CAP(R)Go expression system for scalable production of tailor-made glycoproteins DGAP-News: CEVEC Pharmaceuticals GmbH / Key word(s): Product Launch/Miscellaneous CEVEC introduces CAP(R)Go expression system for scalable production of tailor-made glycoproteins 01.06.2015 / 09:00 …